Tesamorelin
In stockTH9507Human growth hormone-releasing factor (1-44) amide with a trans-3-hexenoyl group on Tyr1, a modification that slows degradation by dipeptidyl peptidase IV. Researchers study its stability and GHRH receptor pharmacology.
Supplied as a single-chamber lyophilized vial with a colour-coded cap (Muscle Growth).
Research literature, not dosing or treatment instructions.
- Tesamorelin acts on the growth hormone-releasing hormone receptor, whose signal transduction and physiology are reviewed. (PMID 8993403)
- A validated UHPLC-MS/MS method detects growth hormone-releasing hormone analogues in urine for anti-doping analysis. (PMID 37806509)
Add the solvent slowly along the vial wall; swirl gently, never shake. Allow to dissolve fully. Six-step guide with photos →
Concentration calculator only. Enter the mass being calculated; blend components are not added automatically. Products are for in-vitro research.
Refer to the product label and supplier documentation for storage conditions. Lot-specific storage and expiry information is not available here.
Each certificate is published with its lot number.
Questions about Tesamorelin
How much published research is there on Tesamorelin?
The research library's PubMed search for Tesamorelin returned 104 records on 5 October 2026, 33 of them reviews. The library lists 3 studies chosen for what they measured. ClinicalTrials.gov lists 24 registered studies naming Tesamorelin (checked 5 October 2026).
Is Tesamorelin an approved medicine?
Medicinal products containing Tesamorelin appear in Drugs@FDA, and the research material we supply is not one of them. Drugs@FDA lists 1 application naming this active ingredient, marketing status as listed: Prescription (checked 5 October 2026). Those are medicinal products. The research material we supply is not one of them. It is supplied for in-vitro laboratory research only, not for human or veterinary use.
What does the hexenoyl group on tesamorelin change?
In the non-clinical paper the hexenoyl modification slowed in vitro degradation in rat, dog and human plasma and prolonged plasma elimination in vivo (PMID 17214611).
How does Tesamorelin differ from Sermorelin?
Sermorelin is the first 29 residues of human growth hormone-releasing hormone, amidated. Tesamorelin is the full 44-residue sequence carrying a trans-3-hexenoyl group on Tyr1. Both act on the GHRH receptor.
How is the identity of Tesamorelin confirmed on a certificate?
A research-grade certificate of analysis typically reports identity by mass spectrometry and purity by HPLC. The mass result is read against the average molecular weight of 5135.9 Da listed on this page. The research library's guide to reading a certificate explains each field.
Is this product for human use?
No. Peptency products are supplied for in-vitro research only. Not for human or veterinary use, not for diagnosis or therapy.
Where can I find shipping information?
Current shipping rates and delivery information are on the Shipping & payment page, and the rates that apply to your order are shown at checkout.
Often studied with
For research use only. Not for human or veterinary use.
What is Tesamorelin?
Tesamorelin is human growth hormone-releasing factor (1-44) amide carrying a trans-3-hexenoyl group on Tyr1, a modification that slows degradation by dipeptidyl peptidase IV. Published work covers non-clinical pharmacology and analytical detection. We supply Tesamorelin as a lyophilized vial for in-vitro laboratory research only.
What are the chemical identifiers of Tesamorelin?
Tesamorelin has the molecular formula C221H366N72O67S, an average molecular weight of 5135.9 Da and CAS number 218949-48-5.
Chemistry checked against PubChem (CID 16137828), 5 October 2026; full chemistry record in the research library.
What does published research on Tesamorelin cover?
A PubMed search for Tesamorelin returned 104 records on 5 October 2026, 33 of them reviews. Our research library lists 3 of these studies, chosen for what they measured.
- Tesamorelin acts on the growth hormone-releasing hormone receptor, whose signal transduction and physiology are reviewed. (Mayo et al., Ann N Y Acad Sci, 1996; PMID 8993403)
- A validated UHPLC-MS/MS method detects growth hormone-releasing hormone analogues in urine for anti-doping analysis. (Cristea et al., Anal Biochem, 2023; PMID 37806509)
Mechanism, every cited study and the regulator records are on the Tesamorelin page of the research library. Papers are listed by what they measured, not as evidence of any use.
How is Tesamorelin supplied and stored?
Tesamorelin is supplied as a lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.
What is the regulatory status of Tesamorelin?
Drugs@FDA lists 1 application naming this active ingredient, marketing status as listed: Prescription (checked 5 October 2026). Those are medicinal products. The research material we supply is not one of them.
The WADA 2026 Prohibited List names this substance under S2.2.4. A WADA entry is a sporting rule, not a statement about legality outside sport.
A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Which related research pages and compounds are listed?
- Tesamorelin: chemistry, literature and regulatory status
- Tesamorelin compared with Sermorelin
- Growth hormone-releasing hormone receptor
- How to read a certificate of analysis
Related compounds in the catalog: